CRS: BJMC
Position: Lab Manager
Position: TB Laboratory Coordinator
CRS:
Position:
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...
